Kyowa Kirin Co., Ltd. 4151

The agreement grants Knight Therapeutics rights to market the medicine for mycosis fungoides and Sézary syndrome subtypes.

GALASHIELS & MARLOW, U.K., September 29, 2026--Kyowa Kirin International, a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), today announced the signing of an exclusive distribution agreement with Knight Therapeutics ("Knight") (TSX: GUD) for the distribution of mogamulizumab in select countries in Latin America.

MONTREAL, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. ("Knight") (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today the signing of an exclusive distribution agreement with Kyowa Kirin International (“KKI”), a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151) (“Kyowa Kirin”), a Japan-based global specialty pharmaceutical company, for mogamulizumab (sold as POTELIGEO® in the United States and Europe) across certain Latin American countries. Under t

Kyowa Kirin (TSE:4151) has come into focus after a broad rethink of pharmaceutical valuations in Tokyo. This has drawn attention to how its share performance lines up with its current earnings profile and research pipeline. Over the past few months, Kyowa Kirin’s share price has come under pressure, with a 30 day share price return of down 11.87% and a 90 day move of down 11.26%, even though the 1 year total shareholder return is slightly positive at 0.49% including dividends. Recent weakness...

Asian stock markets turned in a mixed and generally muted Wednesday, as traders watched Persian Gulf

Opportunities center on earlier genetic diagnosis, targeted FGFR3 therapies, long-acting CNP analogs and oral inhibitors. Developers can improve access, affordability, adherence and lifelong complication management across the US, Europe and Japan.Dublin, Sept. 09, 2026 (GLOBE NEWSWIRE) -- The "Achondroplasia - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering. The achondroplasia market across the seven major markets-the United States, G

President Donald Trump has secured new drug pricing agreements with nine pharmaceutical companies, with an aim to align the prices of drugs in the U.S. with international prices. The companies include Alcon Inc., Astellas Pharma, BeOne Medicines Ltd., BridgeBio, CSL,...

Focused on Medicaid, the new pacts now involve more than just large pharmaceutical companies, but still aren’t expected to meaningfully impact drugmaker profits.

These deals will require the companies to provide MFN prices to state Medicaid programmes nationally.

Under the deals, the drug makers would charge Americans no more than the lowest price paid in other rich countries.

Strengthens Kyowa Kirin’s commitment to expanding access to medicinesReinforces investment in U.S. manufacturing and innovation TOKYO and PRINCETON, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, today announced a voluntary agreement with the U.S. government to improve access and lower the cost of medicines for American patients. As part of the agreement, the company will participate in the GENEROUS mo

Cognizant Technology Solutions recently announced it will support Kyowa Kirin in implementing Benchling, an AI-driven R&D platform, at the Tokyo and Fuji Research Parks in Japan, integrating experiment planning, execution, data capture, and AI tools in a single environment. The engagement highlights Cognizant’s role in life sciences digitalization by providing end-to-end AI and automation support, from platform setup and data migration to ongoing maintenance and workflow optimization for...

Cognizant Technology Solutions stock has climbed sharply in the past month, yet multiple valuation checks still suggest the shares may be pricing in less than the company’s underlying worth. Both an intrinsic value estimate using a Discounted Cash Flow (DCF) approach and market multiple comparisons lean toward the stock trading on the cheap side. The past 30 days brought a 38.7% gain, which puts Cognizant Technology Solutions back in focus after a weaker run over longer periods. Recent work...

Cognizant (NASDAQ: CTSH) today announced that it will support the introduction and implementation of Benchling, the AI platform for R&D at Tokyo Research Park and Fuji Research Park, research sites in Japan operated by Kyowa Kirin Co., Ltd.

The decision to no longer seek approval of amlitelimab is the latest setback for a treatment once hailed as a future blockbuster. One analyst expects Sanofi to now pursue “strategic action” to boost its pipeline.

GALASHIELS, Scotland & MARLOW, England, July 21, 2026--Kyowa Kirin EMEA, a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151), today announced that the European Commission (EC) has approved an expansion of the indication for Crysvita® (burosumab) for the treatment of X-linked hypophosphataemia (XLH), to include infants from 1 month to 1 year of age across the European Union and European Economic Area.

Systemic lupus erythematosus (SLE) is a chronic, complex autoimmune disease that can affect multiple organ systems, with disease severity and clinical manifestations varying considerably among patients. Despite significant advances in understanding its pathophysiology, SLE remains incurable, and current treatment strategies primarily focus on controlling disease activity, achieving remission or low disease activity, preventing irreversible organ damage, minimizing flares, and improving patients'

Seven pharma companies have been selected for the FDA PreCheck pilot – a framework intended to bolster the US drug supply chain.